BioCentury | Jan 20, 2021
Product Development

Trucode reboots as Vera with Abingworth-led $80M series C, disease-modifying therapy for orphan kidney disease

...Pharmaceutical Co. Ltd. are both mAbs in Phase I that target TNFSF13, while telitacicept (RC18, Tai'ai...
BioCentury | Nov 10, 2020

RemeGen’s value surpasses $4B after pricing 2020’s largest biotech IPO

...cancer, autoimmune disease and ophthalmology, with at least two programs in pivotal studies. Its telitacicept (RC18...
BioCentury | Apr 4, 2020

Megarounds for Chinese biopharmas Legend, RemeGen to support late-stage push

...than 10 biologics for autoimmune, cancer and ophthalmology, including commercialization of its two lead candidates RC18...
...and the HER2-targeting antibody-drug conjugate (ADC) RC48. The company has submitted a China NDA for RC18...
BioCentury | Nov 15, 2019
Product Development

Lupus makes leaps with three good pieces of news

...II compound cenerimod is a small molecule S1PR1 modulator; and RemeGen’s Phase II compound telitacicept (RC18...
BioCentury | Nov 13, 2019
Clinical News

Three late-stage wins shift the clinical landscape in SLE

...RemeGen, a subsidiary of Yantai Rongchang Pharmaceutical Co. Ltd., said its TACI-Fc fusion protein telitacicept (RC18...
Items per page:
1 - 5 of 5